Tpp1 Gene Tripeptidyl Peptidase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{- -}}
{{-
| Attribute | Value |
|---|---|
| Gene Symbol | TPP1 |
| Gene Name | Tripeptidyl Peptidase 1 |
| Official Full Name | Tripeptidyl Peptidase 1 |
| Chromosomal Location | 11p15.4 |
| GRCh38 Coordinates | chr11:2,653,227-2,660,457 |
| NCBI Gene ID | 1201 |
| OMIM ID | 607998 |
| Ensembl ID | ENSG00000142149 |
| UniProt ID | O14773 |
| Gene Family | S9 family serine proteases |
The TPP1 gene encodes tripeptidyl peptidase 1 (TPP1), a lysosomal serine protease that cleaves tripeptides from the N-terminus of proteins. This enzyme is essential for the degradation of proteins within lysosomes. Mutations in TPP1 cause Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as Batten disease variant[1].
TPP1 is a 563-amino acid glycoprotein (59 kDa) that functions as a homodimer in the lysosome. It displays tripeptidyl-peptidase activity, cleaving N-terminal tripeptides from various substrates[1].
TPP1 interacts with:
TPP1 mutations cause LINCL, characterized by[1]:
| Feature | Onset | Progression |
|---|---|---|
| Seizures | 2-4 years | Myoclonic, generalized |
| Vision loss | 2-4 years | Progressive, blindness |
| Cognitive decline | 2-4 years | Rapid regression |
| Motor dysfunction | 3-5 years | Ataxia, spasticity |
| Speech loss | 3-5 years | Progressive |
| Death | 6-15 years | Variable |
| Mutation | Type | Frequency | Effect |
|---|---|---|---|
| p.R127X | Nonsense | 30% | No enzyme activity |
| p.A282P | Missense | 15% | Severely reduced |
| p.D283G | Missense | 10% | Reduced activity |
| p.G437S | Missense | 8% | Partial activity |
| p.T75P | Missense | 5% | No activity |
The study of Tpp1 Gene Tripeptidyl Peptidase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: March 2026